文献速递淋巴瘤白血病造血干细胞移植与细胞治疗

表达CD7特异性CAR的CD7编辑T细胞用于治疗T细胞恶性肿瘤

CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
PubMed 文献 · Blood · 2017-05-24

研究针对T细胞恶性肿瘤中CAR T细胞因靶抗原在正常和恶性细胞共享导致的自相残杀问题,通过靶向基因组破坏CD7基因防止自相残杀,使CD7 CAR T细胞扩增且不损害其细胞毒功能。CD7 CAR T细胞对恶性T细胞系和原发肿瘤产生强细胞毒性,并在T-ALL小鼠异种移植模型中具有保护作用。虽然对未编辑的CD7+ T和NK淋巴细胞也有毒性,但CD7编辑的T细胞本身能响应病毒肽,可能对病原体有保护作用。

要点

  • 靶向基因组破坏CD7基因可防止CD7 CAR T细胞的自相残杀并允许其扩增。
  • CD7 CAR T细胞对恶性T细胞系和原发肿瘤有强细胞毒性,并在T-ALL小鼠模型中保护。
  • CD7编辑的T细胞能响应病毒肽,可能对病原体有保护作用。

核心结论

  • 靶抗原的基因组破坏克服了CAR T细胞的自相残杀,并确立了使用CD7 CAR T细胞靶向治疗T细胞恶性肿瘤的可行性。

研究设计与样本

  • 研究通过表达CD7特异性CAR并靶向基因组破坏CD7基因,在体外和T-ALL小鼠异种移植模型中评估CD7 CAR T细胞的功能。

主要发现

  • CD7特异性CAR的表达因残余CD7表达和随之而来的自相残杀而损害转导T细胞的扩增。
  • 靶向基因组破坏CD7基因防止了这种自相残杀,并使CD7 CAR T细胞扩增而不损害其细胞毒功能。
  • CD7 CAR T细胞对恶性T细胞系和原发肿瘤产生强细胞毒性,并在T-ALL小鼠异种移植模型中具有保护作用。
  • CD7 CAR T细胞对未编辑的(CD7+)T和NK淋巴细胞也有毒性。
  • CD7编辑的T细胞本身能响应病毒肽,因此可能对病原体有保护作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Extending the success of chimeric antigen receptor (CAR) T cells to T-cell malignancies is problematic because most target antigens are shared between normal and malignant cells, leading to CAR T-cell fratricide. CD7 is a transmembrane protein highly expressed in acute T-cell leukemia (T-ALL) and in a subset of peripheral T-cell lymphomas. Normal expression of CD7 is largely confined to T cells and natural killer (NK) cells, reducing the risk of off-target-organ toxicity. Here, we show that the expression of a CD7-specific CAR impaired expansion of transduced T cells because of residual CD7 expression and the ensuing fratricide. We demonstrate that targeted genomic disruption of the CD7 gene prevented this fratricide and enabled expansion of CD7 CAR T cells without compromising their cytotoxic function. CD7 CAR T cells produced robust cytotoxicity against malignant T-cell lines and primary tumors and were protective in a mouse xenograft model of T-ALL. Although CD7 CAR T cells were also toxic against unedited (CD7+) T and NK lymphocytes, we show that the CD7-edited T cells themselves can respond to viral peptides and therefore could be protective against pathogens. Hence, genomic disruption of a target antigen overcomes fratricide of CAR T cells and establishes the feasibility of using CD7 CAR T cells for the targeted therapy of T-cell malignancies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Gomes-Silva D, Srinivasan M, Sharma S, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017. PMID: 28539325. doi:10.1182/blood-2017-01-761320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。